0000895345-24-000148.txt : 20240501
0000895345-24-000148.hdr.sgml : 20240501
20240501213222
ACCESSION NUMBER: 0000895345-24-000148
CONFORMED SUBMISSION TYPE: 144
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20240501
DATE AS OF CHANGE: 20240501
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Tango Therapeutics, Inc.
CENTRAL INDEX KEY: 0001819133
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 144
SEC ACT: 1933 Act
SEC FILE NUMBER: 001-39485
FILM NUMBER: 24904873
BUSINESS ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 901
CITY: BOSTON
STATE: MA
ZIP: 02215
BUSINESS PHONE: (857) 320-4900
MAIL ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 901
CITY: BOSTON
STATE: MA
ZIP: 02215
FORMER COMPANY:
FORMER CONFORMED NAME: BCTG Acquisition Corp.
DATE OF NAME CHANGE: 20200723
REPORTING-OWNER:
COMPANY DATA:
COMPANY CONFORMED NAME: MVA Investors, LLC
CENTRAL INDEX KEY: 0001468223
ORGANIZATION NAME:
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 144
BUSINESS ADDRESS:
STREET 1: 12860 EL CAMINO REAL
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 400-3114
MAIL ADDRESS:
STREET 1: 12860 EL CAMINO REAL
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
144
1
primary_doc.xml
144
0001468223
XXXXXXXX
LIVE
0001819133
Tango Therapeutics, Inc.
001-39485
201 Brookline Ave
Suite 901
Boston
MA
02215
857-320-4900
MVA Investors, LLC
member of group owning over 10% of the shares
Common Stock
BofA Securities Inc.
1111 Ave of the Americas
One Bryant Park
New York
NY
10036-6706
75000
577500
106718315
05/01/2024
Nasdaq
Common Stock
04/07/2020
Private Financing
Tango Therapeutics, Inc.
N
21082
04/07/2020
Cash
Common Stock
03/11/2021
Private Financing
Tango Therapeutics, Inc.
N
30442
03/11/2021
Cash
Common Stock
10/12/2022
Open Market Purchases
Tango Therapeutics, Inc.
N
23476
10/12/2022
Cash
Y
Aggregate Market Value as of 4/30/2024.
05/01/2024
/s/ Aaron Davis, Chief Executive Officer